← Back to Search

Pharmacist-led Intervention

Pharmacist-led deprescribing intervention for Caregiver (ALIGN Trial)

N/A
Waitlist Available
Led By Ariel Green, MD, MPH, PhD
Research Sponsored by Johns Hopkins University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
At least one other chronic condition
Five or more chronic medications (to include all prescription and over-the-counter medications, both scheduled and as needed)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up a duration of approximately 8 months
Awards & highlights

ALIGN Trial Summary

This study is evaluating whether a medication review can reduce medication burden for people with dementia.

Eligible Conditions
  • Caregiver
  • Overmedication

ALIGN Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

ALIGN Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and 3 months after enrollment
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and 3 months after enrollment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Acceptability Will be Assessed by the Acceptance Rates for the Pharmacist's Recommendations
Feasibility as Assessed by Percentage of Dyads Who Complete 2 of 2 Pharmacist Phone Calls Based on Documented Status Reports
Feasibility as Assessed by Proportion of Dyads That Opt Out of the Intervention
+5 more
Secondary outcome measures
Family Caregiver Medication Administration Hassles Scale (FCMAHS)
Medication Regimen Complexity Index (MRCI)
Percentage of Participants With Data Elements Available to Calculate the Medication Regimen Complexity Index (pMRCI)
+3 more

ALIGN Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: InterventionExperimental Treatment1 Intervention
The intervention consists of the following: mailing deprescribing educational materials to care partners and people living with dementia (PLWD); dyads will receive a telehealth visit with a clinical pharmacist to discuss the benefits and harms of the patient's medications with the patient and care partner in the context of their goals and preferences; pharmacist- primary care provider (PCP) communication in which the pharmacist provides tailored deprescribing recommendations to the PCP.
Group II: Delayed Intervention (wait list control)Active Control1 Intervention
The delayed intervention consists of the following: mailing deprescribing educational materials to care partners and people living with dementia (PLWD); three months after mailing the deprescribing educational materials, dyads will receive a telehealth visit with a clinical pharmacist to discuss the benefits and harms of the patient's medications with the patient and care partner in the context of their goals and preferences. pharmacist- primary care provider (PCP) communication in which the pharmacist provides tailored deprescribing recommendations to the PCP.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pharmacist-led deprescribing intervention
2021
N/A
~140

Find a Location

Who is running the clinical trial?

Kaiser PermanenteOTHER
534 Previous Clinical Trials
24,110,376 Total Patients Enrolled
Johns Hopkins UniversityLead Sponsor
2,242 Previous Clinical Trials
14,816,499 Total Patients Enrolled
National Institute on Aging (NIA)NIH
1,655 Previous Clinical Trials
28,004,032 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
~37 spots leftby Mar 2025